|
1
|
Delivering affordable cancer care in high-income countries.
|
Lancet Oncol
|
2011
|
12.79
|
|
2
|
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.
|
J Clin Oncol
|
2007
|
6.65
|
|
3
|
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
|
J Clin Oncol
|
2014
|
6.10
|
|
4
|
Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation.
|
Radiographics
|
2015
|
2.93
|
|
5
|
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.
|
Cancer Discov
|
2014
|
2.74
|
|
6
|
Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02.
|
J Clin Oncol
|
2006
|
2.68
|
|
7
|
Doing more harm than good? Do systematic reviews of PET by health technology assessment agencies provide an appraisal of the evidence that is closer to the truth than the primary data supporting its use?
|
J Nucl Med
|
2011
|
2.52
|
|
8
|
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
|
Clin Cancer Res
|
2012
|
2.25
|
|
9
|
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.
|
J Clin Oncol
|
2012
|
2.21
|
|
10
|
Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer.
|
J Clin Oncol
|
2003
|
2.14
|
|
11
|
Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009.
|
Lancet Oncol
|
2009
|
2.12
|
|
12
|
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
|
J Clin Invest
|
2012
|
1.79
|
|
13
|
A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer.
|
Radiother Oncol
|
2006
|
1.73
|
|
14
|
18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
|
J Nucl Med
|
2010
|
1.67
|
|
15
|
Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer.
|
Eur J Nucl Med Mol Imaging
|
2006
|
1.67
|
|
16
|
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
|
Am J Med
|
2002
|
1.62
|
|
17
|
Where do we draw the line? Contouring tumors on positron emission tomography/computed tomography.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.60
|
|
18
|
Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer.
|
Cancer
|
2011
|
1.57
|
|
19
|
Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.
|
Clin Lymphoma
|
2003
|
1.52
|
|
20
|
90Y-edotreotide for metastatic carcinoid refractory to octreotide.
|
J Clin Oncol
|
2010
|
1.49
|
|
21
|
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
|
J Clin Oncol
|
2012
|
1.48
|
|
22
|
Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer.
|
Head Neck
|
2005
|
1.45
|
|
23
|
Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery.
|
J Nucl Med
|
2006
|
1.43
|
|
24
|
Not-so-random errors: randomized controlled trials are not the only evidence of the value of PET.
|
J Nucl Med
|
2012
|
1.43
|
|
25
|
Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration.
|
J Nucl Med
|
2010
|
1.42
|
|
26
|
High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours.
|
J Med Imaging Radiat Oncol
|
2012
|
1.32
|
|
27
|
In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer.
|
Mol Cancer Ther
|
2011
|
1.23
|
|
28
|
Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma.
|
Head Neck
|
2007
|
1.23
|
|
29
|
Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure.
|
Lung Cancer
|
2005
|
1.22
|
|
30
|
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
|
Clin Cancer Res
|
2011
|
1.22
|
|
31
|
Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
|
Int J Radiat Oncol Biol Phys
|
2009
|
1.21
|
|
32
|
How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT?
|
Cancer
|
2007
|
1.21
|
|
33
|
Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.20
|
|
34
|
Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer.
|
Clin Nucl Med
|
2012
|
1.19
|
|
35
|
18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data.
|
J Nucl Med
|
2012
|
1.18
|
|
36
|
Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.14
|
|
37
|
The impact of time between staging PET/CT and definitive chemo-radiation on target volumes and survival in patients with non-small cell lung cancer.
|
Radiother Oncol
|
2013
|
1.13
|
|
38
|
Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by positron emission tomography and treated with curative intent.
|
Int J Gynecol Cancer
|
2009
|
1.13
|
|
39
|
Overview of early response assessment in lymphoma with FDG-PET.
|
Cancer Imaging
|
2007
|
1.12
|
|
40
|
Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy.
|
J Clin Oncol
|
2006
|
1.09
|
|
41
|
Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system.
|
Cancer Imaging
|
2011
|
1.09
|
|
42
|
Does positron emission tomography change management in primary rectal cancer? A prospective assessment.
|
Dis Colon Rectum
|
2004
|
1.08
|
|
43
|
Let's get SEERious: more accurate staging with consequent high management impact is not just stage migration.
|
J Clin Oncol
|
2013
|
1.08
|
|
44
|
The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study.
|
J Nucl Med
|
2002
|
1.08
|
|
45
|
Re: palliative bypass for small bowel carcinoid with mesenteric mass and vascular encasement.
|
ANZ J Surg
|
2015
|
1.06
|
|
46
|
Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.04
|
|
47
|
Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT.
|
J Clin Endocrinol Metab
|
2013
|
1.04
|
|
48
|
Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.
|
J Pharm Pharm Sci
|
2007
|
1.04
|
|
49
|
Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data.
|
J Nucl Med
|
2012
|
1.04
|
|
50
|
Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management.
|
Med J Aust
|
2010
|
1.02
|
|
51
|
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
|
Eur J Cancer
|
2013
|
1.02
|
|
52
|
An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development.
|
Cancer Res
|
2005
|
1.02
|
|
53
|
The extent of resection of FDG-PET hypometabolism relates to outcome of temporal lobectomy.
|
Brain
|
2006
|
1.02
|
|
54
|
Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033.
|
Eur J Nucl Med Mol Imaging
|
2006
|
1.01
|
|
55
|
The impact of PET/CT in the management of recurrent ovarian cancer.
|
Gynecol Oncol
|
2006
|
1.00
|
|
56
|
FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer.
|
Eur J Nucl Med Mol Imaging
|
2006
|
1.00
|
|
57
|
Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour.
|
J Clin Neurosci
|
2009
|
0.99
|
|
58
|
Can structural or functional changes following traumatic brain injury in the rat predict epileptic outcome?
|
Epilepsia
|
2013
|
0.98
|
|
59
|
18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.
|
Skeletal Radiol
|
2011
|
0.98
|
|
60
|
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
|
Eur J Nucl Med Mol Imaging
|
2011
|
0.97
|
|
61
|
Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.
|
Melanoma Res
|
2014
|
0.97
|
|
62
|
Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center.
|
Int J Radiat Oncol Biol Phys
|
2002
|
0.96
|
|
63
|
A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma.
|
Oral Oncol
|
2013
|
0.96
|
|
64
|
Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck.
|
Head Neck
|
2004
|
0.95
|
|
65
|
The clinical significance and management of lesion motion due to respiration during PET/CT scanning.
|
Cancer Imaging
|
2011
|
0.95
|
|
66
|
18F-FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: a 15-year institutional experience.
|
J Nucl Med
|
2013
|
0.94
|
|
67
|
Reproducibility of "intelligent" contouring of gross tumor volume in non-small-cell lung cancer on PET/CT images using a standardized visual method.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.94
|
|
68
|
Radiosynthesis and biological evaluation of L- and D-S-(3-[18F]fluoropropyl)homocysteine for tumor imaging using positron emission tomography.
|
J Med Chem
|
2011
|
0.93
|
|
69
|
The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.
|
Eur J Nucl Med Mol Imaging
|
2011
|
0.93
|
|
70
|
Changing paradigms with molecular imaging of neuroendocrine tumors.
|
Discov Med
|
2012
|
0.93
|
|
71
|
Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.
|
Anticancer Drugs
|
2008
|
0.93
|
|
72
|
68Ga PET/CT ventilation-perfusion imaging for pulmonary embolism: a pilot study with comparison to conventional scintigraphy.
|
J Nucl Med
|
2011
|
0.92
|
|
73
|
Hypometabolism precedes limbic atrophy and spontaneous recurrent seizures in a rat model of TLE.
|
Epilepsia
|
2012
|
0.92
|
|
74
|
High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer.
|
Cancer
|
2010
|
0.92
|
|
75
|
The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer.
|
Semin Nucl Med
|
2012
|
0.92
|
|
76
|
Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging.
|
Mol Cancer Ther
|
2005
|
0.91
|
|
77
|
The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review.
|
Int J Radiat Oncol Biol Phys
|
2008
|
0.91
|
|
78
|
Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2006
|
0.90
|
|
79
|
Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study.
|
Eur J Nucl Med Mol Imaging
|
2008
|
0.89
|
|
80
|
High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications.
|
Eur J Nucl Med Mol Imaging
|
2010
|
0.89
|
|
81
|
Validation of a 4D-PET maximum intensity projection for delineation of an internal target volume.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.89
|
|
82
|
Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease: diagnostic dilemmas and management options.
|
Ann Hematol
|
2004
|
0.88
|
|
83
|
PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate.
|
Dalton Trans
|
2013
|
0.88
|
|
84
|
The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma.
|
Leuk Lymphoma
|
2010
|
0.87
|
|
85
|
Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience.
|
Am J Clin Oncol
|
2004
|
0.87
|
|
86
|
Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
|
J Nucl Med
|
2011
|
0.87
|
|
87
|
Abscopal [corrected] effects after conventional and stereotactic lung irradiation of non-small-cell lung cancer.
|
J Thorac Oncol
|
2013
|
0.86
|
|
88
|
Gallium-68 complex of a macrobicyclic cage amine chelator tethered to two integrin-targeting peptides for diagnostic tumor imaging.
|
Bioconjug Chem
|
2011
|
0.86
|
|
89
|
Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma.
|
Clin Cancer Res
|
2011
|
0.86
|
|
90
|
18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value.
|
J Nucl Med
|
2012
|
0.86
|
|
91
|
[Clinical application of (18)F-FDG PET/CT to staging and treatment effectiveness monitoring of nasopharyngeal carcinoma].
|
Ai Zheng
|
2007
|
0.86
|
|
92
|
High-contrast PET of melanoma using (18)F-MEL050, a selective probe for melanin with predominantly renal clearance.
|
J Nucl Med
|
2010
|
0.85
|
|
93
|
Discovery of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance.
|
J Med Chem
|
2009
|
0.85
|
|
94
|
PET for sarcomas other than gastrointestinal stromal tumors.
|
Oncologist
|
2008
|
0.85
|
|
95
|
Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure.
|
Leuk Lymphoma
|
2007
|
0.85
|
|
96
|
Depression in temporal lobe epilepsy surgery patients: an FDG-PET study.
|
Epilepsia
|
2006
|
0.85
|
|
97
|
PET scanning in lung cancer: current status and future directions.
|
Semin Surg Oncol
|
2003
|
0.84
|
|
98
|
18F-flumazenil: a γ-aminobutyric acid A-specific PET radiotracer for the localization of drug-resistant temporal lobe epilepsy.
|
J Nucl Med
|
2013
|
0.84
|
|
99
|
The genomic landscape of phaeochromocytoma.
|
J Pathol
|
2015
|
0.83
|
|
100
|
Discordant response to chemotherapy detected by PET scanning: unveiling of a second primary cancer.
|
Am J Clin Oncol
|
2002
|
0.83
|
|
101
|
High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience.
|
Cancer Biother Radiopharm
|
2009
|
0.83
|
|
102
|
Impact of PET on radiation therapy planning in lung cancer.
|
Radiol Clin North Am
|
2007
|
0.83
|
|
103
|
Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer.
|
Clin Cancer Res
|
2012
|
0.83
|
|
104
|
The motivations and methodology for high-throughput PET imaging of small animals in cancer research.
|
Eur J Nucl Med Mol Imaging
|
2012
|
0.83
|
|
105
|
Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).
|
Eur J Nucl Med Mol Imaging
|
2014
|
0.83
|
|
106
|
Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours.
|
Eur J Nucl Med Mol Imaging
|
2014
|
0.83
|
|
107
|
Restaging: should we percist without pattern recognition?
|
J Nucl Med
|
2010
|
0.83
|
|
108
|
Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour.
|
Clin Endocrinol (Oxf)
|
2014
|
0.82
|
|
109
|
'MRI-negative PET-positive' temporal lobe epilepsy (TLE) and mesial TLE differ with quantitative MRI and PET: a case control study.
|
BMC Neurol
|
2007
|
0.82
|
|
110
|
The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor.
|
Head Neck
|
2003
|
0.82
|
|
111
|
Atypical brown fat distribution in young males demonstrated on PET/CT.
|
Clin Nucl Med
|
2007
|
0.82
|
|
112
|
Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion.
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.81
|
|
113
|
High-resolution imaging of pulmonary ventilation and perfusion with 68Ga-VQ respiratory gated (4-D) PET/CT.
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.81
|
|
114
|
Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions.
|
Nucl Med Commun
|
2013
|
0.81
|
|
115
|
Clinical experience with the first combined positron emission tomography/computed tomography scanner in Australia.
|
Med J Aust
|
2005
|
0.81
|
|
116
|
Absence of a relationship between tumor ¹⁸F-fluorodeoxyglucose standardized uptake value and survival in patients treated with definitive radiotherapy for non-small-cell lung cancer.
|
J Thorac Oncol
|
2014
|
0.81
|
|
117
|
High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma.
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.81
|
|
118
|
The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification.
|
Cancer Imaging
|
2014
|
0.81
|
|
119
|
The cost-effective use of 18F-FDG PET in the presurgical evaluation of medically refractory focal epilepsy.
|
J Nucl Med
|
2008
|
0.81
|
|
120
|
Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.80
|
|
121
|
Role of PET-CT in the optimization of thoracic radiotherapy.
|
J Thorac Oncol
|
2006
|
0.80
|
|
122
|
Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
|
Eur J Nucl Med Mol Imaging
|
2002
|
0.80
|
|
123
|
An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging.
|
Med Phys
|
2013
|
0.80
|
|
124
|
Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer.
|
J Med Imaging Radiat Oncol
|
2014
|
0.80
|
|
125
|
Radiation changes do not interfere with postchemoradiation restaging of patients with rectal cancer by FDG PET/CT before curative surgical therapy.
|
Int J Radiat Oncol Biol Phys
|
2008
|
0.80
|
|
126
|
Treatment response in the neck: p16+ versus p16- oropharyngeal cancer.
|
J Med Imaging Radiat Oncol
|
2013
|
0.79
|
|
127
|
Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy.
|
J Med Imaging Radiat Oncol
|
2013
|
0.79
|
|
128
|
The role of PET-CT in the management of patients with advanced cancer of the head and neck.
|
Curr Oncol Rep
|
2008
|
0.79
|
|
129
|
In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat.
|
Eur J Nucl Med Mol Imaging
|
2009
|
0.79
|
|
130
|
Detection of synchronous adenocarcinomas and multiple dysplastic polyps with F-18 FDG positron emission tomography in a case of nonfamilial polyposis.
|
Clin Nucl Med
|
2003
|
0.79
|
|
131
|
[18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma.
|
Clin Lymphoma Myeloma
|
2008
|
0.79
|
|
132
|
A prospective observational study of Gallium-68 ventilation and perfusion PET/CT during and after radiotherapy in patients with non-small cell lung cancer.
|
BMC Cancer
|
2014
|
0.79
|
|
133
|
Lamina-specific changes in hippocampal GABA(A)/cBZR and mossy fibre sprouting during and following amygdala kindling in the rat.
|
Neurobiol Dis
|
2009
|
0.78
|
|
134
|
Enhanced white adipose tissue metabolism in iatrogenic Cushing's syndrome with FDG PET/CT.
|
J Clin Endocrinol Metab
|
2014
|
0.78
|
|
135
|
Cancer imaging: quo vadis?
|
Cancer Imaging
|
2014
|
0.78
|
|
136
|
The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas.
|
Expert Rev Mol Diagn
|
2008
|
0.78
|
|
137
|
Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma.
|
J Pediatr Hematol Oncol
|
2016
|
0.78
|
|
138
|
Role of functional imaging in head and neck squamous cell carcinoma: fluorodeoxyglucose positron emission tomography and beyond.
|
Hematol Oncol Clin North Am
|
2008
|
0.77
|
|
139
|
Postchemotherapy and tumor-selective targeting with the La-specific DAB4 monoclonal antibody relates to apoptotic cell clearance.
|
J Nucl Med
|
2014
|
0.77
|
|
140
|
Positron emission tomography and neoadjuvant therapy of breast cancer.
|
J Natl Cancer Inst Monogr
|
2011
|
0.77
|
|
141
|
Segmental hyperperfusion in lobar pneumonia visualized with respiratory-gated four-dimensional pulmonary perfusion positron emission tomography-computed tomography.
|
Am J Respir Crit Care Med
|
2014
|
0.77
|
|
142
|
Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients.
|
Eur J Nucl Med Mol Imaging
|
2012
|
0.77
|
|
143
|
The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data.
|
Radiother Oncol
|
2013
|
0.77
|
|
144
|
Sex and SUVmax: sex-dependent prognostication in early non-small cell lung cancer.
|
J Nucl Med
|
2012
|
0.77
|
|
145
|
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging.
|
Neuroendocrinology
|
2017
|
0.76
|
|
146
|
EEG dipole source localization of interictal spikes in non-lesional TLE with and without hippocampal sclerosis.
|
Epilepsy Res
|
2010
|
0.76
|
|
147
|
Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies.
|
EJNMMI Res
|
2012
|
0.76
|
|
148
|
Inadvertent 2-deoxy-2-[18F]fluoro-D-glucose lymphoscintigraphy: a potential pitfall characterized by hybrid PET-CT.
|
Mol Imaging Biol
|
2002
|
0.76
|
|
149
|
Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy.
|
J Thorac Oncol
|
2015
|
0.75
|
|
150
|
Using positron emission tomography to assess tumor proliferation in non-Hodgkin lymphoma.
|
Leuk Lymphoma
|
2010
|
0.75
|
|
151
|
Health technology assessment and cancer imaging: who should be setting the agenda?
|
Cancer Imaging
|
2004
|
0.75
|
|
152
|
Temporal lobe epilepsy.
|
J Neurosurg
|
2005
|
0.75
|
|
153
|
How can we tell if PET imaging for cancer is cost effective?
|
Lancet Oncol
|
2010
|
0.75
|
|
154
|
Not-so-random errors: randomized controlled trials are not the only evidence of the value of PET--rebuttal.
|
J Nucl Med
|
2013
|
0.75
|
|
155
|
A prospective investigation into the clinical impact of 4D-PET/CT in the characterisation of solitary pulmonary nodules.
|
Cancer Imaging
|
2014
|
0.75
|
|
156
|
What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?
|
Leuk Lymphoma
|
2008
|
0.75
|
|
157
|
White fat, factitious hyperglycemia, and the role of FDG PET to enhance understanding of adipocyte metabolism.
|
EJNMMI Res
|
2011
|
0.75
|
|
158
|
Association between radiation pneumonitis and tumor response in patients with NSCLC treated with chemoradiation.
|
Radiat Oncol
|
2014
|
0.75
|
|
159
|
Incidental findings on follow-up fluorodeoxyglucose positron emission tomography studies in lymphoma patients: beware the outlier.
|
Leuk Lymphoma
|
2009
|
0.75
|
|
160
|
The utility of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in the investigation of patients with disseminated carcinoma of unknown primary origin.
|
Mol Imaging Biol
|
2005
|
0.75
|
|
161
|
PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy.
|
Lung Cancer
|
2005
|
0.75
|
|
162
|
Bifunctional (64)Cu-labelled macrobicyclic cage amine isothiocyanates for immuno-positron emission tomography.
|
Dalton Trans
|
2015
|
0.75
|
|
163
|
Longitudinal Partial Volume Correction in 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Studies of Alzheimer Disease.
|
J Comput Assist Tomogr
|
2015
|
0.75
|
|
164
|
A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy.
|
Haematologica
|
2008
|
0.75
|
|
165
|
THYROPET Study: Is It Biology or Technology That Is the Issue?
|
J Nucl Med
|
2016
|
0.75
|
|
166
|
Only education (not credentialing) truly advances the field.
|
J Nucl Med
|
2011
|
0.75
|
|
167
|
Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.
|
Eur J Nucl Med Mol Imaging
|
2014
|
0.75
|
|
168
|
Imaging, radiation oncology and randomised trials: time for a change?
|
J Med Imaging Radiat Oncol
|
2011
|
0.75
|
|
169
|
Tumour targeting of Auger emitters using DNA ligands conjugated to octreotate.
|
Int J Radiat Biol
|
2012
|
0.75
|
|
170
|
One-step radiosynthesis of 4-nitrophenyl 2-[(18) F]fluoropropionate ([(18) F]NFP); improved preparation of radiolabeled peptides for PET imaging.
|
J Labelled Comp Radiopharm
|
2013
|
0.75
|
|
171
|
Breast lymphatic drainage via the pulmonary lymphatic system.
|
Eur J Nucl Med Mol Imaging
|
2010
|
0.75
|
|
172
|
Respiratory-gated (4D) FDG-PET detects tumour and normal lung response after stereotactic radiotherapy for pulmonary metastases.
|
Acta Oncol
|
2015
|
0.75
|
|
173
|
Scatter limitation to correct for arm movement in PET/CT.
|
Clin Nucl Med
|
2012
|
0.75
|
|
174
|
Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on diagnosis and antimicrobial utilization in patients with high-risk febrile neutropenia.
|
Leuk Lymphoma
|
2012
|
0.75
|
|
175
|
Preclinical characterization of 18F-D-FPHCys, a new amino acid-based PET tracer.
|
Eur J Nucl Med Mol Imaging
|
2011
|
0.75
|
|
176
|
The role of positron emission tomography/computed tomography in planning radiotherapy in endometrial cancer.
|
Int J Gynecol Cancer
|
2015
|
0.75
|